Treace Medical Concepts 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Treace Medical Concepts reported 3rd quarter 2026 revenue of $48.3 million, down 4% compared with the prior-year period, primarily due to a shift toward lower-priced minimally invasive products and lower bunion procedure kit sales.
- Excluding sales to stocking distributors, bunion kit sales volume increased and revenue grew mid-single digits compared with the 3rd quarter of 2025; management said stocking-distributor revenue headwinds would decrease significantly after the 3rd quarter.
- Gross margin was 79.5%, compared with 79.1% in the 3rd quarter of 2025, while operating expenses decreased 10% to $49.9 million.
- Net loss decreased 23% to $12.6 million, or $0.19 per share, from $16.3 million, or $0.26 per share, in the 3rd quarter of 2025; adjusted EBITDA was positive $0.3 million compared with a loss of $2.6 million.
- Year-to-date cash usage was reduced by 53%, or $9.7 million, compared with the same period in 2025, and cash equivalents and marketable securities totaled $39.8 million as of September 30th, 2026.
- Management reported double-digit procedure volume growth and continued market share gains, with approximately 45% of Lapiplasty surgeons having used at least one of Nanoplasty, Perkioplasty, and Speed MTP through the 3rd quarter, up from 40% in Q2.
- Approximately 30% of surgeons who initially became Treace customers through the newer bunion systems now use Lapiplasty products.
- Management said the 5-year ALIGN 3D prospective multicenter study showed positive long-term patient outcomes following the Lapiplasty procedure, including very low radiographic recurrence rates, significant pain reduction, and improvements in validated patient-reported outcome scores.
- Treace fully launched its SuperBite compression screw system in the 3rd quarter and introduced HyperPlate XM, VitaFuse, and CartaBlaster; management said VitaFuse and CartaBlaster were expected to be fully commercialized within the 4th quarter.
- Treace announced successful initial cases with Taylorplasty, its minimally invasive instrumented solution for tailor's bunions, and anticipates full commercialization within Q1 of 2027.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thank you for standing by, and welcome to Treace Medical Concepts Third Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question, you will need to press star 11 on your telephone. You will then hear a message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. Now it's my pleasure to turn the call to Tripp Taylor with Investor Relations.
Please go ahead. Good morning, everyone, and welcome to our Third Quarter 2026 Earnings Conference Call.
Participating from the company today will be John Treace, Chief Executive Officer, and Mark Hehr, Chief Financial Officer. John and Mark will discuss our third quarter financial results and 2026 outlook. We'll then host a question-and-answer session following our prepared remarks. Our press release can be found in the Investor Relations section of our website at investors.treace.com. This call is being recorded and will be archived in the Investor Relations section of our website. Before we begin, we would like to remind you that it's our intent that all forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. Any statements that relate to expectations or predictions of future events and market trends, as well as our estimated results or performance, are forward-looking statements.
All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon currently available information, and Treace Medical assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these statements. Please refer to our SEC filings, including our 2025 Form 10-K and our Form 10-Q for the third quarter of 2026, filed before the market opens today, November 6th, which can be found in the Investor Relations section of our website at investors.treace.com, for a detailed presentation of risks. With that, I will now turn the call over to John.
Thank you, Tripp. Good morning, everyone, and thank you for joining us on our Third Quarter 2026 Earnings Conference Call. We're encouraged by our third quarter performance, driven by double-digit case volume growth and continued market share gains from increasing adoption of our comprehensive portfolio of best-in-class bunion systems and our expanding line of new technologies. During the quarter, we continued to advance our strategic priorities with investments in new products, creating opportunities to build on the foundation that Lapiplasty has established as our surgeon customers adopt more of our new products into their practice. Now we're expanding our presence across a broader range of foot and ankle procedures. We expect the new 2026 product introductions that I will discuss this morning to expand our total addressable market by approximately $700 million.
This strategy has allowed us to leverage our commercial resources to pursue high-impact growth opportunities while maintaining disciplined expense management. We believe this approach positions us to enhance our growth trajectory while improving operating performance over time. With that said, we are narrowing our full-year 2026 revenue guidance to be in the range of $206 million-$210 million. This compares to previous revenue guidance of $204 million-$212 million. Importantly, this outlook assumes a return to growth in the fourth quarter through continued procedure volume increases and as we begin to both lap the ASP mix shift dynamics related to our 2025 product launches and benefit from our 2026 product launches. Now taking a closer look at our growth strategy and the progress we are making across our portfolio. We continue to focus on three key initiatives.
First, leverage our large existing customer base to drive adoption of the three new bunion systems that we launched in Q3 of 2025. Second, continue to build upon our leadership position with Lapiplasty by launching new technologies that can make Lapiplasty even more appealing and attract new surgeon users. Third, expand our product and procedure offerings to expand our TAM and grow wallet share. Now turning to our first initiative, leveraging our existing customer base to drive adoption of our new bunion systems. We continue to see a substantial opportunity to increase utilization of our newer bunion systems, namely Nanoplasty, Percuplasty, and SpeedMTP, across our existing customer base. As we have discussed, Lapiplasty has established a strong position in the Lapidus fusion segment of the bunion market, but that represents only a portion of the overall bunion procedures performed by our surgeons.
Our Nanoplasty and Percuplasty systems give us differentiated 3D minimally invasive options in the large volume osteotomy segment of the market, while our SpeedMTP system extends our reach into the attractive MTP fusion market. These technologies were developed to address different surgeon preferences and procedural approaches, allowing us to participate in a significantly larger portion of the overall bunion market than with Lapiplasty alone. In fact, we estimate that the three new bunion systems we launched in 2025 address the remaining 75% of procedure volumes beyond Lapiplasty. Across our existing customer base, we see an opportunity to increase utilization with this broader portfolio, and the third quarter represented yet another validation that our strategies are working. Through the third quarter, approximately 45% of our Lapiplasty surgeons used at least one of these three new bunion systems in their practice, up from 40% in Q2.
We also continue to see approximately 30% of surgeons who initially became Treace customers through these new bunion systems now using Lapiplasty products, demonstrating the potential for these new systems to create synergies within our business and pull through additional Lapiplasty usage. Shifting to our second initiative, advancing our Lapiplasty technology and expanding its appeal and adoption across a broader surgeon audience. Lapiplasty remains a core focal point of our strategy and what we believe to be the gold standard in the Lapidus fusion segment of the market, a segment that represents roughly 30% of the estimated U.S. bunion procedures. As such, we intend to keep innovating, training surgeons, and supporting Lapiplasty in this largest dollar segment of the bunion market. We also continue to believe in the importance of supporting our technologies with clinical evidence.
At the American Orthopaedic Foot & Ankle Society's annual meeting in September, we announced results from three clinical studies that further strengthen our growing body of clinical evidence across our portfolio. Most notably, our five-year ALIGN3D prospective multicenter study demonstrated positive long-term patient outcomes following the Lapiplasty procedure, including very low radiographic recurrence rates, significant reduction in pain, and significant improvements in key validated patient-reported outcome scores. Our five-year ALIGN3D data represents a first-in-industry milestone for a commercial bunion system. We also shared positive results from our multicenter Adductoplasty and SpeedPlate studies, adding to the evidence supporting our broader technology portfolio. Together, these findings continue to build our differentiated clinical library, providing additional proofs around the durability of our procedures, our patient outcomes, and the performance of our technologies. Turning now to our Lapiplasty product strategy.
Our Lapiplasty Lightning platform is designed to allow for a faster Lapiplasty procedure and to give surgeons even greater control and accuracy in dialing in their 3D correction. We are in final preparations for the anticipated commercial launch of our Lightning system in Q1 2027. We are also focused on expanding the capabilities and utilization of the IntelliGuide PSI platform. This is our patient-specific planning and cut guide system for Lapiplasty bunion and Adductoplasty midfoot corrections. IntelliGuide brings a personalized surgery experience for patients and is designed to provide surgeons greater confidence and control in managing complex deformities and revisional cases while also reducing valuable OR time. We believe the combination of our Lapiplasty Lightning and IntelliGuide PSI platforms can continue to differentiate Treace as the trusted partner for our surgeons and extend our market leadership position in the Lapidus bunion and midfoot deformity segments of the market.
Now turning to our third initiative, expanding into adjacent foot and ankle procedures. Today, we are growing wallet share and becoming a more comprehensive technology partner for our foot and ankle surgeons. If you look back a year or so ago when we offered the Lapiplasty and Adductoplasty systems alone, we estimate these market-leading solutions addressed around 30% of our average customers' overall reconstructive foot and ankle surgery volumes. With the expanded bunion offerings we launched in Q3 of 2025, plus the additional 2026 product launches I will discuss next, we believe we now have the opportunity to serve an estimated 80% or more of our average surgeon's reconstructive surgery volumes. Given this fourth quarter will be our first opportunity to tap into a broader range of elective foot and ankle procedures outside of bunions while also benefiting from seasonally high bunion case volumes with our expanded bunion portfolio.
I would now like to elaborate on the new 2026 product introductions that represent the $700 million TAM expansion and the value they bring to our customers. In the third quarter, we fully launched our SuperBite compression screw system. As a reminder, compression screws are a core fixation technology used throughout the foot and ankle. SuperBite was designed to make screw fixation more efficient by eliminating the step of drilling before placing the screw, a common and time-consuming step performed with conventional screw systems. SuperBite has quickly allowed Treace to participate in a wide range of new procedure opportunities, from incremental reconstructive surgeries in the front of the foot to the back of the foot and to the ankle. Early in its launch, we are pleased with the adoption we are seeing with SuperBite from our existing surgeon customer base.
In many of these SuperBite cases, the surgeon is also utilizing other Treace products, creating additional pull-through opportunities with our expanded portfolio. With SuperBite screws as an entry point into the mid and hindfoot segments of the market, we have built upon this with a new fixation plate offering, namely our HyperPlate XM dynamic compression locking implant. Fusions of the mid and hindfoot bones are generally known for higher nonunion rates. We designed HyperPlate XM implants to provide a highly stable fixation construct through the use of a robust titanium compressing plate with integrated locking screws, with the goal of improving outcomes for these challenging larger bone fusions. Additionally, in Q3, we introduced our VitaFuse bioactive glass graft, a synthetic bone grafting technology that complements our tissue-based CortiFuse graft and our allograft wedges.
These biologic offerings are highly complementary and allow Treace to more fully service our surgeons' broader bone grafting needs throughout the foot and ankle. Adding to our differentiated suite of mid and hindfoot solutions, we also recently introduced our CartiBlaster line of power joint preparation rasps. These are single-use sterile instruments which connect to a powered surgical saw and are designed to facilitate rapid and thorough removal of the cartilage on these larger bone surfaces to prepare them for fusion. We are seeing that CartiBlaster rasps speed up what historically has been a tedious and time-consuming manual process, thus improving the surgeon's overall experience and saving valuable OR time. We believe these four products, SuperBite, HyperPlate, VitaFuse, and CartiBlaster, the latter two which we expect to fully commercialize within the fourth quarter, collectively expand our U.S. TAM by an estimated $400 million.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
